1.Leadless Pacemaker Implantation Following Transcatheter Aortic Valve Implantation Using SAPIEN 3
Taku SHIKAMA ; Mizuki MIURA ; Shinichi SHIRAI ; Masaomi HAYASHI ; Junji MORITA ; Michio NAGASHIMA ; Kenji ANDO
Korean Circulation Journal 2018;48(6):534-535
No abstract available.
Transcatheter Aortic Valve Replacement
2.Successful Use of an eSheath for Failed Introduction of the Evolut R Valve during Transfemoral Transcatheter Aortic Valve Implantation
Umihiko KANEKO ; Ken KOBAYASHI ; Daisuke HACHINOHE ; Keijiro MITSUBE ; Azusa FURUGEN ; Takeshi KAWAMURA ; Ryuji KOSHIMA ; Tsutomu FUJITA
Korean Circulation Journal 2020;50(4):372-373
No abstract available.
Transcatheter Aortic Valve Replacement
3.Atypical Annulus Rupture after Transcatheter Aortic Valve Implantation
Mizuki MIURA ; Shinichi SHIRAI ; Masaomi HAYASHI ; Hiroyuki JINNOUCHI ; Akihiro ISOTANI ; Shinichi KAKUMOTO ; Yoshio ARAI ; Kenji ANDO
Korean Circulation Journal 2018;48(4):332-333
No abstract available.
Rupture
;
Transcatheter Aortic Valve Replacement
4.Successful Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation after CARVAR Operation
Hyungdon KOOK ; Cheol Woong YU ; Seung Hun LEE ; Haim DANENBERG ; Seong Mi PARK
Korean Circulation Journal 2018;48(9):857-860
No abstract available.
Aortic Valve Insufficiency
;
Transcatheter Aortic Valve Replacement
6.3D Printing Model before and after Transcatheter Aortic Valve Implantation for a Better Understanding of the Anatomy of Aortic Root.
Jung Im JUNG ; Yoon Seog KOH ; Kiyuk CHANG
Korean Circulation Journal 2016;46(4):588-589
No abstract available.
Printing, Three-Dimensional*
;
Transcatheter Aortic Valve Replacement*
7.Successful Direct Iliac Transcatheter Aortic Valve Implantation to Overcome Significant Tortuosity of the Thoracic Aorta
Umihiko KANEKO ; Ken KOBAYASHI ; Daisuke HACHINOHE ; Satoshi SUMINO ; Azusa FURUGEN ; Takeshi KAWAMURA ; Hirosato DOI ; Tsutomu FUJITA
Korean Circulation Journal 2018;48(10):949-950
No abstract available.
Aorta, Thoracic
;
Transcatheter Aortic Valve Replacement
8.Dual antiplatelet versus single antiplatelet in post- transcatheter aortic valve implantation/transcatheter aortic valve replacement for stroke prevention: A systematic review and meta-analysis
Ralph Yap ; Douglas Bailon ; Abigail Louise Te-Rosano
Philippine Journal of Cardiology 2021;49(2):26-33
BACKGROUND
There is ambiguity on antiplatelet therapy for post-transcatheter aortic valve replacement (TAVR) patients for stroke prevention, but dual antiplatelet therapy (DAPT) is routinely started despite lack of data on effectiveness and bleeding safety of DAPT versus single antiplatelet therapy (SAPT). This study aims to determine the effectiveness of DAPT versus SAPT in stroke prevention and assess bleeding safety.
METHODSA systematic search was done for randomized clinical trials involving DAPT and SAPT in patients who underwent TAVR. The primary outcome was stroke after 1 year of either DAPT and SAPT and life-threatening bleeding. Secondary end points included all-cause mortality. Trials were identified through systematic searches on the following databases (November 2019): Cochrane, MEDLINE, and Google Scholar and ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform. Risk ratio was used for dichotomous outcomes. Heterogeneity among the studies for the meta-analysis was detected using a χ2 test (0.01 level of significance). Risk-of-bias assessment was done.
RESULTSThere is a lower incidence of stroke in patients on DAPT, but with a higher incidence of life-threatening bleeding and major bleeding. There is also a lower incidence of all-cause mortality in SAPT. The statistical power of this meta-analysis is low due to small population size.
CONCLUSIONSingle antiplatelet therapy is comparable to DAPT in preventing stroke with the added benefit of a lower incidence of life-threatening and major bleeding and a lower incidence of all-cause mortality.
Hemorrhage ; bleeding ; mortality ; Myocardial Infarction ; Stroke ; Transcatheter Aortic Valve Replacement ; transcatheter aortic valve implantation
9.Expanding transcatheter aortic valve replacement into uncharted indications.
The Korean Journal of Internal Medicine 2018;33(3):474-482
Since the first-in-man transcatheter delivery of an aortic valve prosthesis in 2002, the landscape of aortic stenosis therapeutics has shifted dramatically. While initially restricted to non-surgical cases, progressive advances in transcatheter aortic valve replacement and our understanding of its safety and efficacy have expanded its use in intermediate and possibly low surgical risk patients. In this review, we explore the past, present, and future of transcatheter aortic valve replacement.
Aortic Valve
;
Aortic Valve Stenosis
;
Humans
;
Prostheses and Implants
;
Transcatheter Aortic Valve Replacement*
10.Aortic Stenosis and Transcatheter Aortic Valve Implantation: Current Status and Future Directions in Korea
Korean Circulation Journal 2019;49(4):283-297
Transcatheter aortic valve implantation (TAVI) has been accepted as one of primary options for treatment of symptomatic severe aortic stenosis. Although TAVI has been predominantly used for patients at high risk or with old age who were not considered optimal candidates for surgical aortic valve replacement (SAVR), its indication is now expanding toward low risk profile and younger age. Many clinical trials are now ongoing to test the possibility of TAVI for use in patients even with uncharted indications who are not eligible for SAVR in current guidelines but may benefit from valve replacement. Current issues including periprocedural safety, long-term adverse events, hemodynamics and durability associated with TAVI should be also solved for expanding use of TAVI. The review presents current status and future directions of TAVI and discusses perspectives in Korea.
Aortic Valve
;
Aortic Valve Stenosis
;
Hemodynamics
;
Humans
;
Korea
;
Transcatheter Aortic Valve Replacement